German-Austrian recommendations for HIV-therapy in pregnancy - Update May 2003

European Journal of Medical Research

Volumn 9, Issue 6, 2004, Pages 287-303

  Buchholz, Bernd ^a   Gubert, Thomas ^b   Marcus, Ulrich ^c   Beichett, Matthias ^d   Gingelmaier, Andrea ^b   Brockmeyer, Norbert H ^e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d Department of Gynecology and Obstetrics Practice ^*  (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Anti retroviral drugs; HIV status; HIV testing; HIV therapy; Pregnancy; Recommendations

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DELIVERY; DISEASE TRANSMISSION; FEMALE; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MASS SCREENING; NEWBORN; PREGNANCY; PRENATAL CARE;

ANTI-HIV AGENTS; DELIVERY, OBSTETRIC; DISEASE TRANSMISSION, VERTICAL; FEMALE; HEALTH PLANNING GUIDELINES; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MASS SCREENING; PREGNANCY; PRENATAL CARE;

EID: 4243055039     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (109)

1. Bundeszentrale für gesundheitliche Aufklärung, Köln: Aids von A bis Z; Neuauflage 2002
2. Deutsche AIDS-Hilfe e.V.: Der heutige Wissensstand 28. überarbeitete Auflage, 2002
3. Mayaux MJ, Dussaix E, Isopet J, et al.: Maternal Virus 'Load during Pregnancy and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1: The French Perinatal Cohort Studies. J Infect Dis 1997; 175: 172-5
4. Sperling RS, Shapiro DE, Coombs RW, et al.: Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. N Engl J Med 1996; 335: 1621-9
5. Cooper ER, Charurat M, Mofenson L, et al.: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. JAIDS 2002; 29: 484-494
6. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, et al.: Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. JAIDS 2003; 32: 175-183
7. Barret B, Tardieu M, Rustin P, et al.: Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17: 1769-85
8. Blanche S, Tardieu M, Rustin P, et al.: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-89
9. Poirier MC, Patterson TA, Slikker Jr. W, Olivero OA: Incorporation of ′3-Azido-′3-Deoxythymidine (AZT). into fetal DNA and fetal tissue distribution of drug after infusion of pregnant, late-term rhesus macaques with a human-equivalent AZT dose. J Acquir Imm Def Syn 1999; 22: 477-483
10. Meng Q, Walker DM, Olivero OA, et al.: Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA 2000; 97:12667-12671
11. Scalfaro P, Chesaux JJ, Buchwalder PA, et al.: Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med 1998; 24:247-50
12. European Collaborative Study: Exposure to anti-retroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. JAIDS 2003; 32: 380-387
13. Wahn V: Routinemäßige Gabe von Zidovudin an HIV-infizierte Schwangere. Dt Ärztebl 1995; 92:A-3397-8
14. Frenkel LM, Cowles MK, Shapiro DE, et al.: Analysis of the Maternal Components of the AIDS Clinical Trial Group 076 Zidovudine Regimen in the Prevention of Mother-to-Infant Transmission of Human Immunodeficiency Virus Type 1. J Infect Dis 1997;175:971-4
15. Landesmann SH, Kalish LA, Burns DN, et al.: Obstetrical Factors and The Transmission of Human Immunodeficiency Virus Type 1 from Mother to Child. N Engl J Med 1996; 334:1617-23
16. Mandelbrot L, Le Chenadec J, Berrebi A, et al.: Perinatal HIV-1 Transmission. Interaction between Zidovudine Prophylaxis and Mode of Delivery in the French Perinatal Cohort. JAMA 1998; 280:55-60
17. Pitt J, Brambilla D, Reichelderfer P, et al.: Maternal Immunologic and Virologic Risk Factors for Infant Human Immunodeficiency Virus Type 1 Infection: Findings from the Women and Infants Transmission Study. J Infect Dis 1997;175: 567-75
18. Rokos K, Wang H, Seeger J, et al.: Transport of Viruses Through Fetal Membranes: An In Vitro Model of Perinatal Transmission. J Med Virology 1998;54:313-9
19. The European Collaborative Study: Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996; 10:1675-81
20. The European Collaborative Study: Immunological markers in HIV-infected pregnant women. AIDS 1997; 11: 1859-1865
21. Tuomala RE, O'Driscoll PT, Bremer JW, Jennings C, Xu C, et al.: Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in anti-retroviral-experienced women. JID 2003; 187: 375-84
22. Burns DN, Landesman S, Wright, DJ, et al.: Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997; 175:1206-10
23. Gaillard P, Verhofstede C, Mwanyumba F, et al.: Exposure to HIV-1 during delivery and mother-to-child transmission. AIDS 2000; 14: 2341-2348
24. Wright TC Jr, Subbarao S, Ellerbrock TV, et al.: Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol. 2001; 184: 279-85
25. Mwanyumba F, Gaillard P, Inion I, et al.: Placental inflammation and perinatal transmission of HIV-1. JAIDS 2002; 29: 262-69
26. Kind Ch, Rudin Ch, Siegrist C, et al.: Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. AIDS 1998; 12: 205-10
27. Schäfer APA: Die HIV infection in Geburtshilfe und Gynäkologie. Gynäkologe 1996; 29:129-37
28. Schäfer A, Friese K, Lauper U, et al.: Influence of cesarean section before parturition and and-retroviral prophylaxis on the materno-fetal transmission of HIV. 12th World AIDS Conference Geneva, June 28-July 3 1998, Poster LB 12466
29. Deutsch-Österreichische Empfehlungen zur anti-retroviralen Therapie der HIV infection (Juli 2002). Eur J Med Res (2003) 8: 257-274/Update 2004 at URL: http:www.rki.de/INFEKT/AIDS_STD/BR-LINIE/BR-LINIE. HTM
30. Coll O, Fiore S, Floridia M, et al.: Pregnancy and HIV infection: A european consensus on management. AIDS 2002; 16 (Suppl 2):S1-18
31. CDC Public Health Service Task Force: Recommendations for the Use of anti-retroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIN-1 Transmission in the United States. MMWR 1998; 47/ RR2
32. CDC: Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of anti-retroviral Agents in HIV-Infected Adults and Adolescents. MMWR 1998; 47/ RR-5
33. Justman JE Benning L, Danoff A, Minkoff H, et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. JAIDS 2003; 32: 298 302
34. Lorenzi, et al. (Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study): anti-retroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12 (18):F 241-7
35. Wimalasundera RC, Larbalestier N, Smith JH, et al.: Pre-eclampsia, anti-retroviral therapy, and immune reconstitution. Lancet 2002, 360:1152-1154
36. Tuomala RE et al.: anti-retroviral therapy- during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870
37. Conley LJ, Ellerbrock TV, Bush TJ, et al.: HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359: 108-13
38. Rublein J, Calhoun E, Biddle A, et al.: Prevalence of antiretroviral resistance in women of child-bearing potential. 13. World-AlDS-Conference, Durban 2000, Abstr. # MoPe2206
39. Welles SL, Pitt J, Colgrove R, and The Women and Infants Transmission Study Group: HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000;14: 263-71
40. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, Pauli G, Küchefer C: Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Imm Def Syndr 2001; 26: 266-273
41. Eastman PS, Shapiro DE, Coombs RW, et al.: Maternal Viral Genotypic Zidovudine Resistance and Infrequent Zidovudine Therapy to Prevent Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Pediatric Clinical Trial Protocol 076. J Infect Dis 1998; 177:557-64
42. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al.: Lamivudine-Zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-93
43. Jackson JB, Becker-Pergola G, Guay LA, et al.: Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14: F111-F115
44. Kantor R,, Lee E, Johnston E, et al.: Rapid flux in non-nucleoside reverse transcriptase inhibitor resistance mutations among subtype C HIV-1-infected women after single dose nevirapine. Abstr. 78, XH International HIV Drug Resistance Workshop, Los Cabos, Mexico, 10-14 June 2003
45. Sustiva Capsules Product Monograph 1998
46. BMS Warning Letter vom 5. Januar 2001
47. Rich KC, Siegel JN, Jennings, C, et al.: CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis 1995; 172:1221-7
48. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT: Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17: 1195-99
49. Mirochnick M, Fenton T, Gagnier P, et al.: Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178: 368-74
50. Wang Y, Livingston E, Patil S, McKinney RE, Bardeguez AD, Gandia J, et al.: Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999; 180: 1536-41
51. Qian M, Bui T, Ho RJY, et al.: Metabolism of 3′-Azido-′3-Deoxythymidine (AZT) in Human Placental Trophopblasts and Hofbauer Cells. Biochemical Pharmacology 1994; 48: 383-9
52. Agbaria R, Manor E, Barak J, Balzarini J: Phosphorylation of 3′-Azidothymidine in maternal and fetal peripheral blood mononuclear cells during gestation and and at term. JAlDS 2003; 32: 477-481
53. Taylor GP, Lyall EGH, Back D, Ward C, Tudor-Williams G: Pharmacological implications of lengthened in-utero, exposure to nevirapine. Lancet 2000; 355: 2134-5
54. Marzolini C, Rudin C, Decosterd LA, Telenti A, et al.: Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16: 899-93
55. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, Sullivan JL. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J. 2002 Sep;21(9):835-8
56. Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, Culnane M, Sullivan JL. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr. 2003 Jun 1; 33(2): 153-6
57. anti-retroviral Pregnancy Registry Steering Committee: anti-retroviral Pregnancy Registry International, Interim Report for 1 January 1989 through 31 January 2002; Vol.13, No.l. Wilmington NC: Registry Coordinating Center, 2002
58. Larsen WJ: Human Embryology. New York: Churchill Livingstone, 1993
59. Wilson JD, Frazer FC (Hrg.).: Handbook of Teratology, Vol. I. New York: Plenum Press, 1977
60. Spielmann H, Steinhoff R, Schaefer C, et al.: Arzneiverordnung in Schwangerschaft und Stillzeit. 5. Aufl., Stuttgart, Gustav Fischer,1998
61. Connor EM, Sperling RS, Gelber R, et al.: Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment. N Engl J Med 1994; 331:1173-80
62. Chuachoowong R, Shaffer N, Siriwasin W, et al.: Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission, J Inf Dis 2000; 181: 99-106
63. Lallemant M, Jourdain G, Le Coeur S, et al.: A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 343: 982-991
64. Wade NA, Birkhead GS, Warren BL, et al.: Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339:1409-14
65. Mbori-Ngacha D, Richardson BA, Overbaugh J, et al.: Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments. J Virol 2003; 77: 7702-05
66. Ekpini RA, Nkengasong JN, Sibailly T, et al.: Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 2002; 16: 625-30
67. Eastman PS, Shapiro DE, Coombs RW, et al.: Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177:557-64
68. Bardeguez AD, Shapiro DE, Mofenson LM, et al.: Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. JAIDS 2003; 32:170-81
69. Clarke JR, Braganza R, Mirza A, et al.: Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999; 59:364-68 It
70. O'Sullivan M, Boyer P, Scott G, et al.: The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082). Am J Obstet Gynecol 1993; 168:1510-6
71. Garcia, et al.: Maternal levels of plasma human immunodeficiency virus type 1 RNA-and the risk of perinatal transmission. N Eng J Med 1999; 341: 394-402
72. Mofenson LM, et al.: Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Eng J Med 1999; 341: 385-393
73. Newell M-L, et al.: Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13:1377-85
74. Shaffer N, Roongpisuthipong A, Siriwasin W, et al.: Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. J Inf Dis 1999; 179: 590-590
75. Semprini AE: An international randomised trial of mode of delivery in HIV infected women. 12th World AIDS Conference Genevajune 28-July 3 1998, Poster LB 23599
76. The International Perinatal HIV Group: The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. N Eng J Med 1999; 340: 977-87
77. CDC: Recommendations of the U-S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus. MMWR 1994; 43/RR-11
78. Grosch-Wërnef I, Schäfer A, Obladen M, et al.: An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection. AIDS 2000; 14: 2903-2911
79. Burns DN, Landesman S, Muenz LR, et al.: Cigarette smoking, premature rupture of membranes and vertical transmission of HIV1 among women with low CD4+ levels. J Acquir Immune Deficiency Syndr 1994; 7: 718-726
80. Mirochnik M, Dorenbaum A, Blanchard S, et al.: Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: Association with timing of maternal intrapartum nevirapine dose. JAIDS 2003; 33: 153-156
81. Stringer JSA, Sinkala. M, Chapman V, et al.: Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003; 17:1659-65
82. Taha TE, Kumwenda N, Gibbons A, et al.: Neonatal post-exposure prophylaxis with nevirapine and zidovudine reduces mother-to-child transmission of HIV. Abstr. ThOrD1427, XIII International AIDS Conference, Barcelona, July 2002
83. Lallemant M, Gonzague J, Le Coeur S, et al.: Nevirapine during labor and in the neonate significantly improves zidovudine prophylaxis for the prevention of perinatal HIV transmission: results of PHPT-2 first interim analysis. Abstr. LbOr22, XIII International AIDS Conference, Barcelona, July 2002
84. Dabis F, Leroy V, Bequet L, et al.: Effectiveness of a short course of zidovudine + nevirapine to prevent mother-to-child transmission of HIV-1: The Ditrame Plus ANRS 1201 project in Abidjan, Cote d'Ivoire. Abstr. ThOrD1429, XIII International AIDS Conference, Barcelona, July 2002
85. Read J: Duration of ruptured membranes and vertical transmission of HIV-1: a metaanalysis from fifteen prospective cohort studies. 7th Conference on Retroviruses and Opportunistic Infections, January30- February2, 2000, San Francisco; Abstract 659
86. Deutsch-Österreichische Empfehlungen zur postexpositionellen Prophylaxe nach HIV-Exposition (Februar 2001) URL: http://www.rki.de/ INFEKT/AIDS_STD/EXPO/HIV.HTM
87. Guay LA, Musoke P, Fleming T, et al: Intrapartum and neonatal single dose nevirapine compares with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda. HIVNET 012 randomized trial. Lancet 1999; 354: 795-802
88. Moodley D, Moodley J, Coovadia H et al.: A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725-35
89. Owor M, Deseyve M, Duefield C, et al.: The one year safety and efficacy data of the HIVNET 012 trial. 13. World-AIDS-Conference, Durban 2000, Abstr. # LbOr1
90. Marcus U: AIDS und HIV infectionen bei Frauen und Kindern in Deutschland. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 1999; 42: 553-557
91. Shapiro D, Tuomala R, Samelson R, et al. Abstract 12953, 9th Conference on Retroviruses and Opportunistic Infections, Seattle 2002
92. Ioannidis JPA, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, Korber BT, Mayaux MJ, Mofenson LM, Newell M-L, Shapiro DE, Teglas JP, Wilfert CM: Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml. J Inf Dis 2001; 183: 539-45
93. Mandelbrot L, Burgard M, Teglas J-P, et al.: Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS 1999; 13: 2143-2149
94. Debiaggi M, Zara F, Spinillo A, et al.: Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving and-retroviral therapy. Eur J Microbiol Infect Dis 200 1; 20: 91-96
95. Ellerbrock TV, Lennox JL, Clancy KA, et al.: Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001, 184: 28-36
96. Si-Mohamed A, Kazatchkine MD, Goujon C, et al.: Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving anti-retroviral therapy. J Infect Dis 2000, 182:112-122
97. Avidan MS, Groves P, Blott M, et al.: Low complication rate associated with cesarean section under spinal anesthesia for HIV-1 -infected women on anti-retroviral therapy. Anesthesiology 2002, 97: 320-324
98. Read J, Tuomala R, Kpamegan E, et al.: Mode of delivery and postpartum morbidity among HIV-infected women: the women and infants transmission study. JAIDS 2001; 26: 236-245
99. Rodriguez EJ, Spann C, Jamieson D, Lindsay M: Postoperative morbidity associated with cesarean delivery among human immunodeficiency virus-seropositive women. Am J Obstet Gynecol 2001, 184:1108-1111
100. Watts DH, Lambert JS, Stiehm ER et al.: Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of < or = 500/microL. Am J Obstet Gynecol 2000, 183:100-107
101. European Collaborative Study and the Swiss Mother + Child HIV Cohort Study. Combination and-retroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-20
102. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, et al.: Effect of breastfeeding and formula feeding on Transmission of HIV-1. JAMA 2000; 283: 1167-1174
103. Van de Perre P. Transmission of human immunodeficiency virus type 1 through breast-feeding. how can it be prevented? J Infect Dis. 1999 May;179 Suppl 3:S405-7. Review.
104. Nduati RW, John GC, Richardson BA, et al. Human immunodeficiency virus type 1 infected cells in breast milk. Infect Dis 1995; 172: 1461-1468
105. Thiry L, Spencer-Goldberger S, Jonckheer T, et al. Isolation of AIDS virus from cell-free breastmilk of three healthy virus carriers. Lancet 1985 ii: 891-892
106. Haas J, Geiss M, BöhIer T, et al.: False-negative polymerase chain reaction-based diagnosis of human immunodeficiency virus type 1 in children infected with HIV strains of African origin. J Infect Dis 1996; 174:224-225
107. Rossi P, et al.: Early diagnosis of HIV infection in infants - Report of a consensus workshop, Siena, Italy, January 17-18, 1992. JAIDS 1992; 5:1168-1178
108. CENTERS OF DISEASE CONTROL: Guidelines for the use of anti-retroviral agents in pediatric HIV infection. MMWR 1998; 47:1 - 43 Internetadresse: http://www.hivatis.org
109. Capparelli EV, Mirochnick M, Dankner WM, Blanchard S, Mofenson L, McSherry GD, Gay H, Ciupak G, Smith B, Connor JD; Pediatric AIDS Clinical Trials Group 331. Investigators. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr. 2003 Jan;142(1):47-52